Cervarix Reimbursement Will Be Key Challenge For Adoption, GSK Says
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline plans to submit a BLA for the human papillomavirus vaccine by year-end.
You may also be interested in...
Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says
GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.
Cervarix Adjuvant Could Provide Longer Cancer Immune Response, GSK Says
GSK's AS04 adjuvant demonstrates increased immune memory compared to aluminum adjuvants, such as the one used in Merck's Gardasil HPV vaccine.
Hycamtin Combo Therapy Approved For Late-Stage Cervical Cancer
GlaxoSmithKline’s topotecan demonstrates a survival benefit when used in combination with cisplatin, FDA says.